Table 1.
NLCs | DOX EE (%) | ELE EE (%) | DOX DL (%) | ELE DL (%) |
---|---|---|---|---|
DOX/ELE Hyd NLCs | 89.3±3.9 | 87.7±4.2 | 12.1±0.8 | 5.7±0.7 |
DOX/ELE NLCs | 91.8±4.6 | 86.9±3.8 | 10.8±0.9 | 4.9±0.6 |
DOX Hyd NLCs | 90.5±3.7 | – | 9.6±1.1 | – |
ELE Hyd NLCs | – | 88.6±4.9 | – | 5.2±0.8 |
Abbreviations: DL, drug loading; EE, entrapment efficiency; DOX/ELE Hyd NLCs, doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.